Please login to the form below

Not currently logged in
Email:
Password:

Diabetes drug development data announced

Boehringer's linagliptin demonstrates reduction of blood glucose in phase III as Novo Nordisk's degludec achieves proof-of-concept at phase II

Boehringer Ingelheim's linagliptin, a dipeptidyl peptidase (DPP)-4 inhibitor under investigation as a once-daily oral treatment against type 2 diabetes, achieved clinically meaningful reductions in blood glucose, according to phase III study data presented at the 70th Scientific Sessions of the American Diabetes Association (ADA).

In four multicentre, 24-week, randomised, double-blind trials, linagliptin's blood glucose reductions were significant versus placebo and sustained over the study periods. The compound, which has a primarily non-renal route of excretion, is being investigated as a monotherapy and in combination with metformin, with pioglitazone and with voglibose, which is not licensed in the UK.

Also at the ADA meeting, Novo Nordisk presented phase II proof-of-concept data for its investigational insulin degludec, an ultra-long-acting basal insulin, which demonstrated the potential to help achieve target glycaemic control (similar to insulin glargine) when used once-daily or three-times-weekly.

Insulin degludec, a novel insulin molecule with a distinct ultra-long clinical profile, is believed to slow the absorption rate of the insulin into the blood. This leads to a longer profile of action and the possibility of a three-times-weekly dosing regimen in patients with type 2 diabetes. Insulin degludec will now be investigated in the pivotal phase III BEGIN and BOOST trials.

28th June 2010

Share

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Fishawack Health

Fishawack Health is the leading global commercialization partner for the modern life science era. Established in 2001 and headquartered in...

Latest intelligence

Are you ready for the digital health revolution?
In this edition of Delta magazine, we explore how rapid digitalization has transformed the care pathway and reveal how life science companies can succeed in the digital age....
#DemandDiversity: Can new medical publication guidelines help fix diversity in clinical trials?
Over the last 8 months, JAMA have been working on a new set of guidelines for research papers looking to publish with them, which is summarised in their latest editorial...
DATA shutterstock_1818502577-640.jpg
Empowering patients empowers results
Patient-centricity is key when it comes to creating a more flexible, efficient and modern process for clinical trials...

Infographics